Asset Details
Do you wish to reserve the book?
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Do you wish to request the book?
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
2016
Overview
In one comparison from a 2-by-2 factorial trial, 12,705 persons at intermediate cardiovascular risk were assigned to either rosuvastatin or placebo. At 5.6 years, there were significantly fewer participants with cardiovascular events in the rosuvastatin group than in the placebo group.
Cardiovascular diseases cause 18 million deaths per year globally and a similar number of nonfatal cardiovascular events.
1
Elevated low-density lipoprotein (LDL) cholesterol levels account for approximately half the population-attributable risk of myocardial infarction
2
and approximately one quarter of the risk of ischemic stroke.
3
In previous trials, lowering LDL cholesterol levels with statins has been shown to reduce the risk of cardiovascular diseases, but most of the patients enrolled in those trials had vascular disease, elevated lipid levels, elevated inflammatory markers, hypertension, or diabetes.
4
,
5
The association between LDL cholesterol level and cardiovascular disease is graded and has no documented threshold. . . .
Publisher
Massachusetts Medical Society
Subject
/ Cardiovascular Diseases - ethnology
/ Cardiovascular Diseases - mortality
/ Cardiovascular Diseases - prevention & control
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
/ Hypercholesterolemia - drug therapy
/ Lipids
/ Male
/ Rosuvastatin Calcium - administration & dosage
/ Rosuvastatin Calcium - adverse effects
/ Statins
/ Surgery
